AstraZeneca (AZN) Tops Q2 EPS by 17c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts AZN Hot Sheet
Join SI Premium – FREE
Earlier, AstraZeneca (NYSE: AZN) reported Q2 EPS of $1.53, $0.17 better than the analyst estimate of $1.36. Revenue for the quarter came in at $6.66 billion versus the consensus estimate of $6.78 billion.
For earnings history and earnings-related data on AstraZeneca (AZN) click here.
For earnings history and earnings-related data on AstraZeneca (AZN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Tompkins Financial (TMP) Tops Q3 EPS by 5c
- SS&C Technologies shares fall on weak Q4 revenue outlook
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
